Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Pinnacle Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$5,762,963

609 payments

Through program year 2025, Pinnacle Clinical Research LLC is reported as receiving $5,762,963 in research payments, across 609 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $1,835,864 264
2024 Research $2,374,846 177
2023 Research $1,468,843 167
2022 Research $83,411 1

Breakdown

Who paid Research payments · program years 2022–2025
  1. Eli Lilly and Company $2,520,672 39 payments
  2. GlaxoSmithKline, LLC. $1,370,045 271 payments
  3. Regeneron Pharmaceuticals, Inc. $548,995 137 payments
  4. Amgen Inc. $358,571 3 payments
  5. PTC Therapeutics, Inc. $286,208 27 payments
  6. Madrigal Pharmaceuticals $165,060 62 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $140,834 49 payments
  8. Genentech, Inc. $122,556 4 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $83,411 1 payment
  10. Intercept Pharma Europe Ltd. $64,104 2 payments
Studies the money was for Research payments · program years 2022–2025
  1. 17 B-Hydroxysteroid Dehydrogenase Type 13 Minimization for the Treatme $1,370,045 271 payments
  2. A Phase 3B Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide 2.4 MG in Adults Who Have Obesity Or Overweight With Weight-Related Comorbidities (Surmount-5) $660,909 2 payments
  3. A Study of Ly3298176 (Tirzepatide) for the Maintenance of Body Weight Reduction in Participants Who Have Obesity Or Overweight With Weight-Related Comorbidities $557,152 6 payments
  4. A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors $548,995 137 payments
  5. A Phase 3B, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide 2.4 MG in Adults Who Have Obesity Or Overweight With Weight-Related Comorbidities (Surmount-5) $318,833 5 payments
  6. An Open-Label Single-Dose Study to Evaluate the Pharmacokinetics of AMG 133 in Participants with Varying Degrees of Hepatic Impairment $313,004 1 payment
  7. A Parallel-Group, Single-Dose, Phase 1, Open-Label Study to Investigate the Pharmacokinetics of Ly3437943 in Participants With Hepatic Impairment Compared With Healthy Participants $295,602 2 payments
  8. A Phase 1 Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Sepiapterin $286,208 27 payments
  9. A Study of Ly3298176 (Tirzepatide) for the Maintenance of Body Weight Reduction in Participants Who Have Obesity Or Overweight With Weight-Related Comorbidities $166,511 2 payments
  10. A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) $165,060 62 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record